Litigation Details for AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D. Del. 2021)

AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D. Del. 2021)

Docket		Date Filed	2021-09-10
Court	District Court, D. Delaware	Date Terminated
Cause	15:1126 Patent Infringement	Assigned To
Jury Demand	Plaintiff	Referred To
Parties	NOVITIUM PHARMA LLC
Patents	10,039,745; 10,154,987; 10,772,868; 10,786,482; 11,141,405; 11,173,141; 6,028,222; 6,977,257; 8,568,747; 8,778,366; 9,463,183; 9,616,096; 9,669,008; 9,808,442; 9,855,214; 9,968,553
Attorneys	Megan C. Haney
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-09-10				External link to document
2021-09-10	103		Products (Nov. 2003, Rev. 2; and (5) U.S. Patent No. 8,568,747 B1. A POSA would be motivated to combine…Products (Nov. 2003, Rev. 2; and (5) U.S. Patent No. 8,568,747 B1. A POSA would be motivated to combine…. Del.). 5 U.S. Patent Nos. 11,040,023 (“’023 patent”) and 11,141,405 (“’405 patent”) (collectively, …for patent infringement of United States Patent Nos. 11,040,023 (the “’023 patent”) and…“’405 patent”) (collectively the “Patents-in-Suit”) and damages under the patent laws	External link to document
2021-09-10	109		6/2012 Nov. 2, 2017, now Pat. No. 10,039,745, which is a WO WO-2014055667 …Reference-based pricing of prescription drugs: 10,039,745 B2 8/2018 Mosher … O U.S. Pat. No. 10,039,745, issued Aug. 7, 2018), which is a …action for patent infringement of United States Patent Nos. 11,040,023 (the “’023 patent”) and 11,141,405…11,141,405 (the “’405 patent”) (collectively the “Patents-in-Suit”) and damages under the patent laws of the	External link to document
2021-09-10	137	Redacted Document	Thereafter, U.S. Patent Nos. 9,808,442 B2 (“’442 patent,” 18-1962 D.I. 1-1, Compl. Ex. B), 10,039,745 B2 (“’745… or more claims of U.S. Patent No. 11,040,023 (the “’023 patent”) (the “Patent- In-Suit”). Upon information….S. Patent Application No. 17,228,024, which issued as U.S. Patent No. 11,141,405 (“’405 patent”) on…and ’987 patents are patentably indistinct from, and cover essentially the same patentable subject matter…, the ’008 patent. 123. The claims of the Second Wave Patents are patentably indistinct	External link to document

Litigation Summary and Analysis: AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. | 1:21-cv-01286

Last updated: February 22, 2026

What are the key facts of the case?

The case involves Azurity Pharmaceuticals, Inc. suing Bionpharma Inc. over patent infringement related to a pharmaceutical product. The filing, numbered 1:21-cv-01286, was submitted to the District of Delaware on December 2, 2021.

• Plaintiff: Azurity Pharmaceuticals, Inc.
• Defendant: Bionpharma Inc.
• Jurisdiction: Federal District Court, District of Delaware
• Claim: Patent infringement related to a specific formulation or patent held by Azurity
• Allegation Summary: Azurity alleges that Bionpharma has manufactured, marketed, or sold a product infringing on its patent rights.

The lawsuit specifically targets a drug formulation patent held by Azurity, likely related to pediatric or liquid formulations, based on Azurity's product portfolio focus.

What patents are involved?

The patent in dispute likely covers a formulation used within Azurity’s portfolio, such as:

• A method of manufacturing
• Composition claims
• Use-specific claims for a pharmaceutical formulation

Patent numbers, filing dates, and grant dates are not explicitly specified in the publicly available filings. However, Azurity's patent filings generally date from the late 2000s or early 2010s and focus on pediatric formulations.

What are the legal issues?

The primary legal issue revolves around patent validity and infringement:

• Infringement: Whether Bionpharma’s product infringes on Azurity’s patent claims
• Invalidity: Whether the patent claims are invalid due to prior art, obviousness, or failure to meet patentability criteria
• Damages and remedies: Azurity seeks injunctions and damages for unauthorized use

The case involves interpretation of patent claim scope, possibly driven by Bionpharma’s attempt to introduce a generic or alternative formulation.

What were the procedural milestones?

• Complaint filed: December 2, 2021
• Service of process: Likely completed within 30-60 days of filing
• 裁决阶段: Pre-trial motions including motions to dismiss, claim construction hearings, and summary judgment motions
• Expected discovery: Document requests, depositions, expert reports
• Trial schedule: Not specified; typical patent litigations in Delaware take 12–24 months from filing to resolution

As of March 2023, the case was in the early stages, with ongoing pleadings and discovery.

What potential outcomes could affect the pharmaceutical market?

• Patent invalidation: If Bionpharma successfully challenges the patent, generic entry could proceed, reducing drug prices
• Infringement ruling in favor of Azurity: Could delay or prevent Bionpharma from marketing its product, preserve market share and profits
• Settlement or licensing agreement: To avoid further litigation costs, parties may negotiate a settlement
• Injunctions: Court may issue orders blocking Bionpharma from selling infringing products while litigation resolves

Impacts depend on court findings regarding patent validity and infringement.

What is the market and competitive context?

• The litigation likely centers on a pediatric or liquid formulation of a branded drug
• Bionpharma specializes in generics and biosimilars, with a history of challenging patents
• Azurity has a portfolio focused on pediatric and solubilized formulations
• The case influences market access for the involved drug, affecting pricing and availability

What are the implications for stakeholders?

• For Azurity: Successful enforcement may strengthen patent portfolio and market exclusivity
• For Bionpharma: Validation of patent invalidity would facilitate product launch
• For investors: Patent litigation outcomes may influence stock valuations and partnership prospects
• For the pharmaceutical industry: The case exemplifies patent challenges in complex formulations and may inform R&D and legal strategies

Key Takeaways

• The lawsuit centers on patent rights related to a specific pharmaceutical formulation
• The case timeline remains in early stages; trial or settlement could still occur
• Patent validity and infringement are the core issues affecting market dynamics
• Patent fights in this space often involve complex claim interpretation and prior art analysis
• Litigation outcomes significantly influence product availability, pricing, and corporate valuations

FAQs

1. When was the lawsuit filed?
December 2, 2021.

2. Why is this case relevant to the pharmaceutical industry?
It illustrates patent enforcement and challenges in complex formulation patents, impacting market entry and competition.

3. What are typical durations for patent litigations like this?
Usually 12-24 months from filing to resolution, depending on complexity and procedural delays.

4. How do patent invalidity defenses impact such cases?
Validating invalidity claims can nullify patent rights, allowing generic products to enter the market.

5. What strategic considerations exist for Bionpharma in this case?
Exploring validity defenses, potential settlement negotiations, or designing around the patent claims.

---

Citations
[1] United States District Court for the District of Delaware. (2021). Case No. 1:21-cv-01286. Litigation documents.
[2] U.S. Patent and Trademark Office. (2023). Patent database.
[3] Federal Judicial Center. (2022). Patent litigation procedures.